Pfizer

HERO-TOGETHER: A Safety Surveillance Study of Post- Vaccination Events of Interest among People Vaccinated Against COVID-19

Posted on by Jodi Snare

Page last updated September 2, 2025

ClinicalTrials.gov#: NCT04342806
Study Design: Prospective Observational Study
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Emily O'Brien
Institution: Duke Clinical Research Institute
PCORnet® Network Partner: The Coordinating Center for PCORnet®
Funder: Pfizer
Funding Date: 2020
Study Duration: 2020 – 2022
Participating PCORnet® Clinical Research Networks: GPC, OneFlorida+, PaTH, REACHnet, STAR, The Coordinating Center for PCORnet®
Therapeutic Area: Infectious Disease
Status: Completed

Research Question(s): Can a research registry of people working in healthcare help to answer important questions about the COVID-19 pandemic on medications, vaccines and healthcare worker well-being?

Estimating the Burden of Nonalcoholic Steatohepatitis Using a Multistate Electronic Health Record Data Network

Posted on by Jodi Snare

Page last updated September 2, 2025

Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Patient partners or engagement
Principal Investigator: Kathleen McTigue
Institution: University of Pittsburgh School of Medicine
PCORnet® Network Partner: PaTH
Funder: Pfizer
Funding Date: 2020
Study Duration: 2020 – 2023
Participating PCORnet® Clinical Research Networks: OneFlorida+, PaTH, REACHnet
Therapeutic Area: Hepatology
Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
Age Range:

Research Question(s):

  1. How do patients with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) compare with those who do not have these diagnoses?
  2. How is risk for liver fibrosis (calculated from 4 validated scores) distributed among patients with and without diagnoses for NASH or NAFLD?